Dianthus Therapeutics (DNTH) Other Accumulated Expenses (2022 - 2023)
Dianthus Therapeutics' quarterly Other Accumulated Expenses came in at $279000.0 in Q2 2023, up 24.55% quarter-over-quarter from $224000.0 in Q1 2023.
Dianthus Therapeutics has reported Other Accumulated Expenses for 2 years, with the latest figure at $279000.0 in Q2 2023.
- For the quarter ending Q2 2023, Other Accumulated Expenses changed N/A year-over-year to $279000.0; the trailing twelve-month figure through Jun 2023 stood at $279000.0 (changed N/A YoY), and the FY2022 full-year result was $364000.0, changed N/A from the prior year.
- Other Accumulated Expenses for Q2 2023 stood at $279000.0, up from $224000.0 in the prior quarter.
- The five-year high for Other Accumulated Expenses was $364000.0 in Q4 2022, with the low at $224000.0 in Q1 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Dianthus Therapeutics | 4.02 Bn | 3.62 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 279,000.00 |
| Mar 31, 2023 | 224,000.00 |
| Dec 31, 2022 | 364,000.00 |